By Ed Silverman
June 9, 2026
Pharmalot Columnist, Senior Writer
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. Who could ask for anything more? Actually, we could — it is time to reheat the kettle for another cuppa stimulation. Our choice today is raspberry hibiscus. And here is a helpful tip: A teaspoon of honey enhances the flavors splendidly. Of course, you are invited to join us. For the full experience, we are hawking replicas — take a look . Meanwhile, here are a few tidbits to help you along. As always, do keep in touch. We appreciate feedback, criticism, and tips. …
GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology , STAT writes. The deal is the latest in a run of biopharma acquisitions in recent months, as large and even midsize companies have been looking to bolster their pipelines as some of their key products face looming generic competition. This latest deal is one of the largest in the recent buying spree, and GSK’s largest in years. Nuvalent designs targeted cancer therapies, with two molecules both under U.S. Food and Drug Administration review for types of non-small cell lung cancer. They could be approved this year. The deal will give GSK, which has focused on gynecologic cancers as well as multiple myeloma, a broader lung cancer portfolio.
Merck and Gilead Sciences disclosed that an experimental long-acting pill combining two HIV medicines had met its primary efficacy goal in final-stage trials , Bloomberg News notes. The companies said that in two large trials, a once-weekly combination pill containing Merck’s islatravir and Gilead’s lenacapavir had proven to be “non-inferior” to standard pill regimens that are taken daily. If approved by regulators, the new combination could become the first once-weekly pill for the treatment of HIV. A once-weekly pill would provide a less-frequent dosing option that does not require an injection. Gilead currently sells a different version of lenacapavir as a twice-yearly injectable to prevent the disease under the brand name Yeztugo.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
Read the full article at STAT News →📄Source document: FDA Review of Non-Small Cell Lung Cancer Therapies→4 reports
STAT NewsIndependentCenter12 days agoGlaxoSmithKline (GSK) has agreed to acquire Nuvalent, a cancer drug developer, in a $10.6 billion deal. Nuvalent is developing targeted cancer therapies, with two molecules currently under FDA review for non-small cell lung cancer. The acquisition is part of a broader trend in the biopharma industry, where companies are expanding their pipelines amid pressure from generic competition.
Bias read (Center): The article provides factual information about a business transaction between pharmaceutical companies without taking a stance or using biased language. It focuses on market dynamics and does not engage in political commentary or favor any particular side.
QuartzIndependentCenter12 days agoQuartz reports that British pharmaceutical company GSK is acquiring lung cancer biotech firm Nuvalent in an all-cash transaction described as its largest deal in over a decade. The acquisition gives GSK two late-stage lung cancer drugs currently under review by the U.S. Food and Drug Administration.
Bias read (Center): The report is a straightforward factual account of a corporate acquisition using neutral business language with no political framing or loaded terms.
MarketWatchParty-alignedCenter12 days agoU.K. pharmaceutical giant GSK has agreed to acquire U.S.-based biotech firm Nuvalent for $10.6 billion, marking its largest acquisition in eight years. The move aims to strengthen GSK's cancer drug portfolio, which it had previously reduced.
Bias read (Center): The article reports on a business transaction without taking a stance on political issues. It focuses on corporate strategy and financial decisions rather than policy, ideology, or partisan matters.
STAT NewsIndependentCenter12 days ago STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6BGSK has agreed to acquire Nuvalent, a cancer-focused biotechnology company, for $10.6 billion. This acquisition is part of a broader trend in the biopharmaceutical industry where larger firms are acquiring smaller companies to strengthen their drug development pipelines amid upcoming generic competition.
Bias read (Center): The article provides factual information about a business acquisition without taking a stance or using biased language. It focuses on financial details and industry trends without emphasizing any particular political perspective.
United States